An overview of levodopa in the management of restless legs syndrome in a dialysis population: Pharmacokinetics, clinical trials, and complications of therapy

Annals of Pharmacotherapy

Volumn 33, Issue 1, 1999, Pages 86-92

  Janzen, Laverne ^a,c   Rich, Jay A ^b   Vercaigne, Lavern M ^c  

^a HEALTH SCIENCES CENTRE   (Canada)

^b Shoppers Drug Mart Charleswood   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Benserazide; Carbidopa; Dialysis; Levodopa; Restless legs syndrome

Indexed keywords

BENSERAZIDE; CARBIDOPA; LEVODOPA;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL; REBOUND; RESTLESS LEGS SYNDROME; REVIEW; SYMPTOMATOLOGY;

CLINICAL TRIALS; HUMANS; KIDNEY FAILURE, CHRONIC; LEVODOPA; MEDLINE; RENAL DIALYSIS; RESTLESS LEGS SYNDROME; SYNDROME;

EID: 0032908706     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18024     Document Type: Review

References (36)

1. Winkelman JW, Chertow GM, Lazarus JM. Restless legs syndrome in end-stage renal disease. Am J Kidney Dis 1996;28:372-8.
2. O'Keeffe ST, Noel J, Lavan JN. Restless legs syndrome in the elderly. Postgrad Med J 1993;69:701-3.
3. Walters AS, for The International Restless Legs Syndrome Study Group. Toward a better definition of the restless legs syndrome. Mov Dis 1995; 10:634-42.
4. Akpinar S. Restless leg syndrome treatment with dopaminergic drugs. Clin Neuropharmacol 1987;10:69-79.
5. von Scheele C, Levodopa in restless legs. Lancet 1986;2:426-7.
6. von Scheele C, Kempi V. Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up. Arch Neurol 1990;47:1223-4.
7. Montplaisir J, Godbout R, Poirier G, Bedard MA. Restless leg syndrome and periodic movements in sleep: physiopathology and treatment with L-dopa, Clin Neuropharmacol 1986;9:456-63.
8. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless leg syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988;38:1845-8.
9. Becker PM, Jamieson AO, Brown WD. Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: response and complications of extended treatment in 49 cases. Sleep 1993;16:713-6.
10. Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993;43:445.
11. Earley CJ, Allen RP. Pergolide and carbidopa / levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996;19:801-10.
12. Sandyk R. Bernick C, Lee SM, Stern LZ, Iacono RP, Bamford CR. L-dopa in uremic patients with the restless legs syndrome. Intern J Neurosci 1987;35:233-5.
13. Trenkwalder C, Stiasny K, Pollmacher TH, Wetter TH, Schwarz J, Kohnen R, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995;18:681-8.
14. Walker SL, Fine A, Kryger MH. L-dopa/carbidopa for nocturnal movement disorders in uremia. Sleep 1996;19:214-8.
15. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-13.
16. Allen RP, Kaplan PW, Buchholz DW, Earley CJ, Walters JK. Double-blinded, placebo controlled comparison of high dose propoxyphene and moderate dose carbidopa/levodopa for treatment of periodic limb movements in sleep (abstract). Sleep Res 1992;21:166.
17. Kaplan P, Allen R, Buchholz D, Walters J. A double-blind placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993;16:717-23.
18. Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty S, et al. Successful treatment of the idiopathic restless leg syndrome in a randomized double-blind trial of oxycodone versus placebo, Sleep 1993; 16:327-32.
19. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984;310:483-8.
20. Baruzzi A, Contin M, Riva R, Procaccianti G, Albani F, Tonello C, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987;10: 527-37.
21. Yen KC, August TF, Bush DF, Lasseter KC, Musson DG, Schwartz S, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989:39(suppl 2):25-37.
22. LeWitt PA, Nelson MV, Berchou RC, Galloway MP, Kesaree N, Kareti D, et al. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 1989:39(suppl 2):45-53.
23. Campbell NRC, Hasinoff B. Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. Clin Pharmacol Ther 1989; 45:220-5.
24. Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet 1996;30:463-81.
25. Sharpless NS, Muenter MD, Tyce GM, Owen CA Jr. 3-Methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease. Clin Chim Acta 1972;37: 359-69.
26. Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 1987;13:141-78.
27. Silber MH, Shepard JW, Wisbey JA. Pergolide in the management of restless legs syndrome - an extended study. Sleep 1997;20:878-82.
28. Walters AS, Hening WA, Kavey N, Chokroverty S, Gidro-Frank S. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 1988;24:455-8.
29. Telstad W, Sorenson O, Larsen S, Lillevold PE, Stensrud P, Nyberg-Hansen R. Treatment of the restless legs syndrome with carbamazepine: a double-blind study. BMJ 1984;288:444-6.
30. Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty S, et al. Successful treatment of the idiopathic restless leg syndrome in a randomized double-blind trial ofoxycodone versus placebo. Sleep 1993; 16:327-32.
31. Hening WA, Walters AS. Successful long-term therapy of the restless legs syndrome with opioid medication (abstract). Sleep Res 1989;18: 241.
32. Wagner ML, Walters AS, Coleman RG, Hening WA, Grasing K, Chokroverty S. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 1996;19:52-8.
33. Handwerker JV, Palmer RF. Clonidine in the treatement of "restless legs" syndrome. N Engl J Med 1985;313:1228-9.
34. Ausserwuinler M, Schmidt P. Successful clonidine treatment of restless legs syndrome in chronic kidney insufficiency. Schweiz Med Wochenschr 1989;19:184-6.
35. Montplaisir J, Lapierre O, Warnes H, Pelletier G. The treatment of the restless legs syndrome with or without periodic leg movements in sleep. Sleep 1992;15:391-5.
36. Adler CH. Treatment of restless legs syndrome with gabapentin. Clin Neuropharmacol 1997;20:148-51.